Michael A. Nauck
Elite in Type 2 Diabetes (T2D)

Michael A. Nauck

St. Josef Hospital, 
Bochum, NW, DE 
Elite in Type 2 Diabetes (T2D)
St. Josef Hospital, 
Bochum, NW, DE 
OverviewLocationsClinical Research

Overview

Michael Nauck practices in Bochum, Germany. Mr. Nauck is rated as an Elite expert by MediFind in the treatment of Type 2 Diabetes (T2D). His top areas of expertise are Type 2 Diabetes (T2D), Low Blood Sugar, Insulinoma, and Acute Pancreatitis.

His clinical research consists of co-authoring 186 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 148 articles and participated in 2 clinical trials in the study of Type 2 Diabetes (T2D).

Gender
Male

Locations

St. Josef Hospital, Bochum, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
Antidiabetic Effects of Adding a DPP-4 Inhibitor (Sitagliptin) to Pre-Existing Treatment With an Incretin Mimetic (Liraglutide) in Patients With Type 2 Diabetes Treated With Metformin
Antidiabetic Effects of Adding a DPP-4 Inhibitor (Sitagliptin) to Pre-Existing Treatment With an Incretin Mimetic (Liraglutide) in Patients With Type 2 Diabetes Treated With Metformin
Enrollment Status: Completed
Publish Date: January 30, 2017
Intervention Type: Drug, Other
Study Phase: Phase 3
View 1 Less Clinical Trial

186 Total Publications

Localization of benign insulinomas with a radionuclide tracer targeting the GLP-1 receptor with pegylated exendin-4.
Localization of benign insulinomas with a radionuclide tracer targeting the GLP-1 receptor with pegylated exendin-4.
Journal: The Journal of clinical endocrinology and metabolism
Published: May 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Nauck's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile